Mice and human express a single inhibitory FcγR, FcγRIIb. FcγRIIb is expressed on B lymphocytes and inflammatory cells. 11 FcγRIIb is a single subunit protein with 2 tyrosine residues in the cytoplasmic domain. IC binding to FcγRIIb results in phosphorylation of immunoreceptor tyrosine-based inhibition motif resulting in recruitment of SHP-1 (Src homology region 2 domain-containing phsophatase-1), a phosphatase that dephosphorylates immunoreceptor tyrosine-based activation motifs, thus regulating the activating FcγRs-induced proinflammatory signaling. 11 Besides regulating the function of the activating FcγRs, FcγRIIb negatively regulates B-cell receptor function, thus regulating antibody production. 11 The loss of FcγRIIb has been shown to exacerbate pathology in number of autoimmune disease models. 16, 17 Studies are emerging to address the role for FcγRs in the progression of atherosclerosis. [18] [19] [20] [21] [22] [23] Studies from our laboratory and others have shown that the deficiency of all the 3 activating FcγRs in apolipoprotein E (apoE)-Fcγ chain −/− mice lead to attenuated lesions. 18, 19 Similarly, the deficiency of FcγRIII, in LDL receptor-deficient (LDLR −/− ) 20 or apolipoprotein E single knockout (apoE) −/−23 hyperlipidemic mouse models, has shown reduced atherosclerotic lesions. Based on this premise, we hypothesized that the loss of inhibitory FcγRIIb would exacerbate atherosclerosis.
In this report, we generated hyperlipidemic apoE −/− mice lacking FcγRIIb expression (congenic to C57BL/6, hereafter referred as apoE-FcγRIIb B6 −/− ) and tested our hypothesis. In contrary to expectations, our findings using apoE-FcγRIIb B6 −/− mice had reduced atherosclerotic lesions. During the course of our studies, it was reported that the deficiency of FcγRIIb on a mixed background (apoE-FcγRIIb 129/B6 −/− ) resulted in exacerbated lesions. 21 Because our findings are the opposite of those generated using apoE-FcγRIIb 129/B6 −/− mice on a mixed background, we have performed careful analyses of the congenic apoE-FcγRIIb B6 −/− mouse strain in a diet-induced atherosclerosis. We have also evaluated the mechanism(s) contributing to the unexpected attenuated lesions in apoE-FcγRIIb B6 −/− mice. As previous reports have revealed a possible epistatic mechanism contributing to the difference in lupus susceptibility in FcγRIIb single knockout mouse models, 24, 25 we asked whether the difference in atherosclerotic phenotype is owed to a possible epistatic mechanism.
Materials and Methods
Materials and methods are available in the online-only Data Supplement.
Results

ApoE-FcγRIIb B6 −/− Mice Show Reduced Atherosclerotic Lesions
To determine whether inhibitory FcγRIIb deficiency accelerates the progression of atherosclerosis, apoE-FcγRIIb double knockout mice (apoE-FcγRIIb B6 −/− ) were generated. Genotype analyses confirmed complete knockout for FcγRIIb in apoE −/− background ( Figure IA in the online-only Data Supplement). Spontaneous atherosclerotic lesions in apoE −/− and apoE-FcγRIIb B6 −/− mice (male) fed chow diet were determined by staining aortic sinus sections with Oil Red O ( Figure 1A ). Quantitative analyses showed ≈50% reduction in lesion area (P<0.01) in apoE-FcγRIIb B6 −/− mice compared with apoE −/− mice ( Figure 1B ). As our finding was unexpected, the experiments were repeated using male and female mice. We observed decreased lesions in both male and female apoE-FcγRIIb B6 −/− mice fed chow diet (data not shown). To ascertain the unexpected finding, we then investigated whether FcγRIIb deficiency also affected accelerated atherosclerosis in mice fed a high-fat diet. The lesion area in apoE-FcγRIIb B6 −/− male mice fed a high-fat diet was significantly reduced compared with apoE −/− mice ( Figure 1C and 1D). Similar results were seen with female apoE-FcγRIIb B6 −/− mice fed a high-fat diet ( Figure 1E and 1F), demonstrating that attenuated atherosclerosis in apoE-FcγRIIb B6 −/− mice is not a function of sex. Enface analyses of the descending aorta and aortic arch also showed reduced lesions in apoE-FcγRIIb B6 −/− compared with apoE −/− mice ( Figure IB and IC in the online-only Data Supplement), suggesting that the results are not unique to the aortic root.
Inhibitory FcγRIIb Expressed on Hematopoietic Cells Is Sufficient to Contribute to the Atherosclerotic Lesions
We performed bone marrow chimera experiments to (1) confirm the unexpected findings from the global deletion of FcγRIIb and (2) address the relative contribution of FcγRIIb expressed on hematopoietic and vascular cells to the progression of atherosclerosis. Bone marrow cells from apoE −/− or apoE-FcγRIIb B6 −/− donor mice were transplanted to lethally irradiated apoE −/− recipient mice. Deletion of the FcγRIIb in hematopoietic cells was confirmed by the genomic polymerase chain reaction analyses (Figure 2A ). The atherosclerotic lesion area in apoE −/− recipient mice receiving apoE-FcγRIIb B6 -deficient bone marrow cells was significantly smaller (50% reduction [P<0.01] than those receiving apoE −/− bone marrow ( Figure 2B and 2C). These findings confirm that the loss of inhibitory FcγRIIb does not exacerbate atherosclerosis. In addition, these findings reveal that the loss of FcγRIIb expression on hematopoietic cells is sufficient to reduce atherosclerotic lesions.
FcγRIIb Deficiency Does Not Alter Plasma Cholesterol Levels
To determine the molecular mechanisms contributing to the decreased atherosclerotic lesions in apoE-FcγRIIb B6 −/− mice, plasma levels of cholesterol (total-cholesterol, nonhigh-density lipoprotein-cholesterol, and high-density lipoprotein-cholesterol) and triglyceride were quantified. Plasma cholesterol and triglyceride levels were similar in chow diet fed apoE-FcγRIIb B6 −/− and apoE −/− mice (Figure IIA-IID in the online-only Data Supplement). Moreover, plasma total cholesterol levels were also similar in a high-fat diet fed apoE-FcγRIIb B6 −/− and apoE −/− mice ( Figure IIE in the online-only Data Supplement). These findings suggest that the reduction in atherosclerotic lesions in apoE-FcγRIIb B6 −/− mice is independent of plasma lipid levels.
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Anti-OxLDL IgG Levels Were Elevated in apoE-FcγRIIb B6 −/− Mice
As studies have shown that FcγRIIb −/− mice have elevated IgG levels resulting from the lack of inhibition of B-cell receptor, 16 we quantified anti-oxLDL antibody (IgG subclasses and IgM) in apoE-FcγRIIb B6 −/− mice. Not surprisingly, plasma levels of total IgG1 and IgG2a were higher in apoE-FcγRIIb B6 −/− mice compared with apoE −/− mice, whereas IgG2b was not different between both strains (Figure IIIA-IIIC in the onlineonly Data Supplement). Anti-malondialdehyde-modified LDL (MDALDL) IgG subclass analyses showed that anti-MDALDL IgG2a (Th1 response), anti-MDALDL IgG1, and IgG2b (Th2 response) were elevated in apoE-FcγRIIb B6 −/− mice fed a chow diet ( Figure 3A-3C ). Analyses of the anti-oxLDL IgG subclasses also showed analogous findings ( Figure 3E -3G). The total mouse IgG2a/IgG1 ratio was not significantly different ( Figure IIID in the online-only Data Supplement). However, the anti-MDALDL IgG2a/IgG1 ( Figure 3D ) and anti-oxLDL IgG2a/IgG1 ( Figure 3H ) ratios were lower in apoE-FcγRIIb B6 −/− mice than in apoE −/− mice. As elevated levels of circulating anti-oxLDL IgG could promote the formation of apoB-IC, we quantified apoB-IC-containing IgG1 and IgG2a subclasses. Notably, circulating apoB-IC IgG1 levels were higher than apoB-IC IgG2a IC in apoE-FcγRIIb B6 −/− mice ( Figure IIIE Circulating levels of total IgM were also elevated ( Figure 3I ). Interestingly, plasma anti-MDALDL IgM and anti-oxLDL IgM levels were found to be higher in apoE-FcγRIIb B6 −/− mice than in apoE −/− mice ( Figure 3K and 3L). Earlier studies have suggested that anti-oxLDL IgM, natural antibody response is atheroprotective. 7, 26 Hence, we investigated whether the elevated anti-oxLDL IgM response also represent natural antibody (binds to oxLDL and phosphorylcholine) using phosphorylcholine-keyhole limpet hemocyanin (KLH) as antigen. The specificity of natural antibody assay was determined using E06, a mouse IgM monoclonal antibody (also known as natural antibody), that recognizes oxLDL and phosphorylcholine portion of PC-KLH. 27, 28 E06 specifically bound to phosphorylcholine-KLH with no detectable binding to KLH ( Figure IIIG in the online-only Data Supplement). Natural antibody-recognizing phosphorylcholine was elevated in apoE-FcγRIIb B6 −/− mice compared with that in apoE −/− mice ( Figure 3L ), suggesting that elevated levels of atheroprotective natural antibody might contribute to the attenuated lesions in apoE-FcγRIIb B6 −/− mice.
Attenuated Atherosclerotic Lesion in apoE-FcγRIIb B6 −/− Mice Is Associated With Increased Anti-Inflammatory Cytokines by CD4 + T Cells
Next, we investigated whether altered T-cell responses contribute to attenuated lesions in apoE-FcγRIIb B6 −/− mice. Analyses of CD4 + and CD8 + T-cell populations showed that CD4 + , CD8 + cells and CD4/CD8 ratio were not altered in apoE-FcγRIIb B6 Figure 4E and 4F). Th17 cells, a subset of CD4 cells secreting IL-17, have been implicated in proinflammatory responses 29, 30 and IL-17 has been implicated in the progression of atherosclerosis. 31 Consistent with this model, we found that IL-17 secretion by the activated CD4 + T cells from apoE −/− mice was significantly higher than that from of apoE-FcγRIIb B6 −/− cells ( Figure 4G ). As, transforming growth factor (TGF)-β and IL-6 are essential for the generation of Th17 cells and IL-17 secretion in mice, 29, 30 we quantified secretion of TGF-β by activated T cells. Activated apoE-FcγRIIb B6 −/− CD4 + secrete about twice as much TGF-β than the activated CD4 + cells from apoE −/− mice ( Figure 4H ).
If anti-inflammatory skewing in apoE-FcγRIIb B6 −/− mice contributes to atheroprotection, we would predict that the T cells at lesion sites would be polarized to T-helper cells (Th2)/ T-regulatory cells (Treg) in apoE-FcγRIIb B6 −/− mice. Thus, we quantified mRNA levels of Th1 and Th2 cytokines in aortas isolated from apoE −/− and apoE-FcγRIIb B6 −/− mice. Interferon-γ mRNA expression at the lesion site was similar in apoE- 
Elevated IL-10 and Reduced IL-6 Secretion by FcγRIIb B6 −/− Macrophages
FcγRIIb is expressed on B lymphocytes and myeloid cells including dendritic cells and macrophages. 11 Hence to determine whether the deficiency of inhibitory FcγRIIb on macrophages promotes anti-inflammatory responses, we stimulated bone marrow-derived macrophages (BMDMs) with platebound MDALDL-IC and quantified cytokine release. BMDMs from wild-type mice were treated with plate-bound MDALDL-IC or ovalbumin-IC to determine the specificity of plate-bound IC formation and IC-mediated cytokine response. Rabbit anti-MDA IgG specifically bound to MDALDL-coated Figure 5A and 5B ). Similar findings were obtained when LPS was used to activate macrophages ( Figure 5D and 5E). IL-12 secretion, if present, was below the levels of detection (data not shown). Notably, apoE-FcγRIIb B6 −/− BMDM showed high levels of MDALDL-IC-or LPS-induced IL-10 secretion ( Figure 5C and 5F) . These findings suggest that elevated IL-10 secretion by macrophages, in part, contributes to the attenuated atherosclerotic lesions in apoE-FcγRIIb B6 −/− mice.
Possible Epistatic Mechanism Contributing to Reduced Inflammatory Response in FcγRIIb in Congenic Background
Our results are puzzling and contrast to a recent report showing augmented lesions in apoE-FcγRIIb 129/B6 −/− mice in a mixed genetic background. 21 Because our animals are congenic to C57BL/6, we undertook a detailed analysis to determine whether the difference in the atherosclerotic lesion burden could be because of the use of different mouse strains. Genomic analyses to determine congenic background revealed that the genome of the FcγRIIb single knockout on the mixed background (FcγRIIb 129/B6 −/− ) is 50% 129/SV and 48% C57BL/B6 ( Figure VII To investigate whether indeed the mixed versus congenic genetic background contributed to the difference in atherosclerotic lesions, peritoneal macrophages from mixed FcγRIIb 129/B6 −/− and congenic FcγRIIb B6 −/− mice were activated with IC or LPS, and inflammatory cytokine expression was quantified. To eliminate the effects of atherogenic diets or hyperlipidemia, we used FcγRIIb single knockout mice fed a chow diet. We found dramatic differences in cytokine expression between mixed FcγRIIb 129/B6 −/− and congenic FcγRIIb B6 −/− macrophages. Wild-type peritoneal macrophages treated with IC induced il1beta, il6, and mcp-1 expression ( Figure 6A-6C ). IC-induced il1beta, il6, and mcp-1 mRNA expression was significantly reduced (>50%) in macrophages from FcγRIIb B6 −/− in a congenic background compared with macrophages from mixed FcγRIIb 129/B6 −/− mice ( Figure 6A-6C) . Similarly, LPS-mediated proinflammatory cytokine response was elevated in FcγRIIb 129/B6 −/− macrophages, whereas the expression of il1beta, il6, and mcp-1 was blunted in macrophages from FcγRIIb B6 −/− mice on the congenic background ( Figure 6E-6G) . Interestingly, IC-or LPS-induced IL-10, an anti-inflammatory cytokine, expression ( Figure 6D and 6H) was significantly higher (4-fold) in congenic FcγRIIb B6 −/− versus mixed FcγRIIb 129/B6 −/− macrophages. The mouse fcgr2b, lupus-associated sle1a, and members of signaling leukocyte association molecule (Slam) cluster in sle1b are localized in the distal telomeric region of chromosome 1 ( Figure 6I ). 24, 36, 37 Hence, we investigated whether the expression of Slam genes ( Table I in (Figure 6J-6M ). These findings suggest that possible strain-specific epistatic mechanism may contribute to the anti-inflammatory cytokine response by inflammatory cells in congenic apoE-FcγRIIb B6 −/− mice.
Discussion
In the present study, we tested the hypothesis that the loss of inhibitory FcγRIIb in hyperlipidemic apoE −/− mice exacerbates atherosclerosis. In contrary to our hypothesis, we showed that arterial lesions are significantly reduced in both male and female apoE-FcγRIIb B6 −/− mice on chow or highfat diets. Interestingly, bone marrow chimera studies confirmed this unexpected finding. Specifically, apoE −/− mice transplanted with bone marrow from apoE-FcγRIIb B6 −/− mice developed significantly less atherosclerosis. This chimeric strategy also established that the attenuated lesion in apoE-FcγRIIb B6 −/− mice depends on FcγRIIb expressed on hematopoietic cells. The reduction in diet-induced atherosclerotic lesions in the apoE-FcγRIIb B6 −/− mice was associated with the increased secretion of IL-10 by activated CD4 + cells and macrophages. Moreover, analysis of IC-mediated cytokine induction revealed that, in contrast to macrophages from mixed background (FcγRIIb 129/B6 −/− ), FcγRIIb B6 −/− (congenic to C57BL/B6) expressed higher IL-10 and lower IL-1β and IL-6 mRNA. These findings suggest that the decreased atherosclerotic lesion seen in apoE-FcγRIIb B6 −/− mice is likely a result of elevated anti-inflammatory responses by innate and adaptive immune cells.
Studies using hyperlipidemic apoE −/− mice lacking all the activating FcγRs (apoE-Fcγ chain −/− ) 18, 19 or loss of FcγRIII, one of the activating FcγRs, in apoE −/− , 23 or LDLR −/− mice 20 have shown that the loss of activating FcγRs decreases atherosclerosis. Based on our earlier findings using apoE-Fcγ chain −/− mice, 19 we hypothesized that removal of the inhibitory FcγRIIb in a hyperlipidemic apoE −/− mice (congenic to C57BL/6) would accelerate plaque progression and exacerbate atherosclerotic lesions. Surprisingly, apoE-FcγRIIb B6 −/− mice have less atherosclerosis. During our studies, a recent report 21 showed apoE-FcγRIIb 129/B6 −/− mice on a mixed genetic background had increased atherosclerotic lesions only in male mice (fed chow diet for 37 weeks). Because of the differences in our findings, 21 we carefully investigated the role of inhibitory FcγRIIb in diet-induced atherosclerosis using several approaches including lesion analyses in male and female mice, chow or a high-fat diet, and by reconstituting the immune system of irradiated apoE −/− mice with bone marrows from apoE −/− or apoE-FcγRIIb B6 −/− mice. All studies confirmed decreased lesions, regardless of sex or diet. Moreover, the bone marrow chimera results established that the loss of FcγRIIb on hematopoietic cells is sufficient to produce atheroprotection. This effect was not limited to the aortic sinus, as similar results were seen in the descending aorta. Moreover, we also tested the unexpected finding in a carotid artery ligation model of carotid atherosclerosis (in collaboration with Dr Lennartz). Independently, attenuated lesions were also seen in apoE-FcγRIIb B6 −/− in a carotid artery ligation model. 38 Thus, the findings from the current study suggest that the expression of FcγRIIb on hematopoietic cells contributes to the progression of atherosclerosis in apoE −/− mice.
Although our studies using FcγRIIb B6 −/− mice show reduced lesions, bone marrow transfer of FcγRIIb B6 −/− mice to LDLR −/− female mice produced a modest increase in atherosclerotic lesions in the descending aorta. 22 Similar to our findings (Figure 4 ), activated T cells from LDLR-FcγRIIb −/− chimeric mice produced more IL-4 and IL-10. 22 Although there was no difference in interferon-γ (Th1), the authors concluded that an imbalance between the Th1 and Th2 response could have contributed to the increased lesions in their study. Moreover, IgG subclass analyses of anti-oxLDL and anti-MDALDL IgG and possible circulating levels of apoB-IC revealed a predominant IgG1 (anti-inflammatory Th2) response compared with IgG2a isotype (proinflammatory, Th1). ApoE −/− and LDLR −/− mice have been widely used to study mechanisms contributing to atherosclerosis. 39, 40 However, there are differences between these 2 hyperlipidemic models. The composition of LDL isolated from LDLR −/− mice is different from apoE −/− mice. 41 Studies by Febbraio group have reported that apoE-CD36 −/− mice have reduced lesions compared with apoE −/− mice, 42 whereas lesion analyses revealed no difference in lesions in LDLR-CD36 −/− mice compared with LDLR −/− mice. 43 Moreover, proteomic analyses showed difference in the proteins secreted by lipid-loaded macrophages from apoE −/− versus LDLR −/− mice. 44 Recently, LPS-induced proinflammatory response has been shown to be reduced in LDLR −/− macrophages. 45 However, LPS-induced proinflammatory responses are enhanced in apoE −/− macrophages. 46 These studies highlight differences in the inflammatory responses in the apoE −/− and LDLR −/− hyperlipidemic mouse models. It is conceivable that such strain-specific differences could account for the disparity of results in this report using apoE-FcγRIIb B6 −/− mice and the recent report using LDLR −/− mice. 22 Earlier studies have suggested that anti-oxLDL IgM, natural antibody response is atheroprotective. 7, 26 Our data are consistent with this model in that anti-oxLDL IgM levels were high in the plasma from our apoE-FcγRIIb B6 −/− mice. In addition, we directly tested for natural IgM antibody. Our findings showed plasma levels of natural IgM antibody-recognizing phosphorylcholine also was elevated in apoE-FcγRIIb B6 −/− mice. Together these results support the possibility that elevated natural IgM antibody levels in apoE-FcγRIIb B6 −/− mice may be atheroprotective. However, this possibility needs to be resolved by passive transfer of anti-oxLDL IgM antibodies. In addition, our plasma anti-oxLDL IgG subtype analyses suggest a shift from proinflammatory Th1 to anti-inflammatory Th2 or Treg in apoE-FcγRIIb B6 −/− mice, another mechanism leading to atheroprotection. CD4 + Th1 cells have been shown to promote atherosclerosis. 47, 48 Although Th2 cytokine levels (ie, IL-4) were elevated in our study, deletion of IL-4 in apoE −/− mice does not enhance lesions. 49, 50 Moreover, t-bet and gata3 expression (Th1 and Th2 transcription factors) that was similar in apoE-FcγRIIb B6 −/− and apoE −/− mice suggest that a Th1/Th2 imbalance may not be contributing to the attenuated lesions seen in apoE-FcγRIIb B6 −/− mice. Our findings showed activated CD4 + T cells secrete less IL-17A, a Th17 cytokine. The role of IL-17 in the progression of atherosclerosis is controversial. Several studies including a recent report showed that IL-17 is proatherogenic, [51] [52] [53] [54] [55] [56] [57] whereas other studies suggest that it may be atheroprotective. 58, 59 The disparate results may result from the different strains, diets, and approaches used. More studies are needed to define the role for IL-17 in atherosclerosis. We also showed secretion of IL-10 is elevated several fold in apoE-FcγRIIb B6 −/− mice. In addition, the expression of foxp3, the transcription factor regulating Treg generation and thought to contribute to attenuated lesions in hyperlipidemic models, 55, 60 was significantly elevated in the atherosclerotic prone aortic arch of apoE-FcγRIIb B6 −/− mice. We showed that TGF-β secretion by activated T cells was elevated in apoE-FcγRIIb B6 −/− mice, whereas IC-or LPSactivated IL-6 secretion by BMDM was reduced. DC-derived IL-6 secretion is critical for the generation and differentiation of Th17 cells. 61, 62 Collectively, these findings suggest that conditions that promote Treg formation, and/or secretion of antiatherogenic IL-10, and TGF-β 63,64 play a role in restricting lesion progression in apoE-FcγRIIb B6 −/− mice. We showed convincingly that deficiency of FcγRIIb in hyperlipidemic apoE −/− mice in a congenic C57BL/6 background resulted in decreased lesions in multiple approaches. However, our results are puzzling as well as contrary to the recent report. 21 Notably, earlier studies using apoE-CD36 −/− (mixed) backcrossed 4 generations to C57BL/6 (≈93% C57BL/6) showed reduced lesions, 42 whereas in a later study using apoE-CD36 −/− congenic to C57BL/B6 (≈99% C57BL/6) background does not ameliorate atherosclerosis. 65 Similar findings were also reported for Rag (lacking T and B cells) deficiency in LDLR −/− background. 66 Because of the earlier reports, to avoid genetic background influencing the phenotype, we used FcγRIIb B6 −/− mice (backcrossed 12 generations to C57BL/6), to generate apoE-FcγRIIb B6 −/− mice congenic to C57BL/6, in contrary to the mixed FcγRIIb 129/B6 −/− mice used in the recent report 21 (http://jaxmice.jax.org/strain/002848. html). ApoE-FcγRIIb 129/B6 −/− mice were generated by intercrossing (F1 male and female) apoE-FcγRIIb 129/B6 heterozygous in a mixed background, 21 raising a possibility that the apoE-FcγRIIb 129/B6 −/− mouse strain used may not be congenic to C57BL/6. Moreover, macrophages from FcγRIIb 129/B6 −/− mixed background have elevated proinflammatory cytokine response, whereas the expression of proinflammatory cytokine response was significantly reduced in congenic FcγRIIb B6 −/− mice. On the contrary, IL-10 secretion by macrophages from FcγRIIb 129/B6 −/− mixed background is lower than congenic FcγRIIb B6 −/− mice. Precise genetic mapping revealed that Fcgr2b gene is localized between the lupus-associated sle1a and sle1b subloci 24 in the distal telomeric end of chromosome 1. Several reports have suggested that lupus-associated Slam gene clusters are also localized in the Sle1b, lupus-associated loci in chromosome 1. 24, 36, 37 Analyses of slam cluster genes revealed that cd84, ly9, slamf1, and slamf6 expression was upregulated in B lymphocytes of B6.Sle1 mice compared with B6 mice. 24 We showed that the expression of slam cluster genes is upregulated in FcγRIIb 129/B6 −/− mice, but not in FcγRIIb B6 −/− or apoE-FcγRIIb B6 −/− mice. This finding is analogous to an earlier report showing upregulation of Slam cluster genes in B lymphocytes of a lupus-prone B6.Sle1b compared with B6 mice. 24, 36, 37 Recently, Boross et al 25 has presented evidence that FcγRIIb 129/ B6 −/− on a mixed genetic background (using FcγRIIb 129 −/− backcrossed 8 generation into C57BL/6) developed spontaneous autoimmune disease, whereas FcγRIIb B6 −/− generated using C57BL/6-derived ES cells did not. 25 These studies suggest that the 129-derived lupus-associated loci is essential to induce lupus even in the absence of FcγRIIb. Notably, knocking in the FcγRIIb promoter regions from autoimmune prone mouse (NZB, NOD, 129/sv, and MRL) into C57BL/6 mice promotes an autoimmune lupus phenotype. 67 Similarly, human studies have determined that an FcγRIIb polymorphism that results in loss of function has been associated with lupus in systemic lupus erythematosus patients. 68, 69 Interestingly, transfer of hematopoietic stem cells from a carrier expressing a functionally impaired FcγRIIb allele (FcγRIIb Thr232 ) into an immuno-compromised humanized mice resulted in higher autoantibody production compared with fully functional FcγRIIb Ile232 carrier. 70 These studies provide evidence for a link between functionally impaired FcγRIIb and the lupus phenotype. Based on our findings and the reports on FcγRIIb polymorphism linked to lupus, it is tempting to speculate that in the presence of lupus-associated gene, loss of FcγRIIb −/− may result in exacerbated atherosclerotic lesions. However, more detailed studies are warranted to compare the effect of lupus-associated genes in the presence or absence of FcγRIIb on the progression of atherosclerosis. These studies are being pursued in our laboratory.
In summary, FcγRIIb deficiency reduces atherosclerosis in hyperlipidemic apoE −/− mice. The attenuated lesions in apoE-FcγRIIb B6 −/− mice are associated with the promotion of Tregs and increased secretion of atheroprotective cytokines such as IL-10 and TGF-β. Importantly, the genetic background such as lupus-resistant may contribute to reduced FcγR-mediated IL-6 and elevated IL-10 secretion. These studies collectively suggest that the epistatic mechanism linking lupus-associated gene in combination with FcγRIIb deficiency may contribute to exacerbated lesions.
